Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Howell

Showing results (31-40 of 339) with videos related to

Pageof 34
Sort By:
Clinical Breast Cancer|November 10, 2005
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancerAnthony Howell, Gershon Y Locker
Breast Cancer Research : BCR|July 10, 2015
Can the breast screening appointment be used to provide risk assessment and prevention advice?D Gareth Evans, Anthony Howell
Breast Cancer Research : BCR|December 19, 2003
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?D Gareth Evans, Anthony Howell
Endocrine-Related Cancer|August 23, 2005
Overview of the impact of conventional systemic therapies on breast cancerAnthony Howell, Andrew M Wardley
Nature Clinical Practice. Oncology|February 8, 2006
Does HER2 overexpression affect response to endocrine therapy in advanced cancer?Andrew M Wardley, Anthony Howell
Advances in Experimental Medicine and Biology|January 17, 2025
Targeting Oestrogen Receptor Signalling in Breast Cancer TherapySacha J Howell, Anthony Howell
Lancet (London, England)|April 27, 2005
Preventing cancer, cardiovascular disease, and diabetesAndrew G Renehan, Anthony Howell
Lancet (London, England)|May 4, 2013
Breast cancer prevention: SERMs come of ageAnthony Howell, D Gareth Evans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2012
Are we ready for online tools in decision making for BRCA1/2 mutation carriers?D Gareth Evans, Anthony Howell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopiesD Gareth Evans, Anthony Howell
Pageof 34

Showing results (31-40 of 339) with videos related to

Sort By:
Pageof 34
Clinical Breast Cancer|November 10, 2005
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancerAnthony Howell, Gershon Y Locker
Breast Cancer Research : BCR|July 10, 2015
Can the breast screening appointment be used to provide risk assessment and prevention advice?D Gareth Evans, Anthony Howell
Breast Cancer Research : BCR|December 19, 2003
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?D Gareth Evans, Anthony Howell
Endocrine-Related Cancer|August 23, 2005
Overview of the impact of conventional systemic therapies on breast cancerAnthony Howell, Andrew M Wardley
Nature Clinical Practice. Oncology|February 8, 2006
Does HER2 overexpression affect response to endocrine therapy in advanced cancer?Andrew M Wardley, Anthony Howell
Advances in Experimental Medicine and Biology|January 17, 2025
Targeting Oestrogen Receptor Signalling in Breast Cancer TherapySacha J Howell, Anthony Howell
Lancet (London, England)|April 27, 2005
Preventing cancer, cardiovascular disease, and diabetesAndrew G Renehan, Anthony Howell
Lancet (London, England)|May 4, 2013
Breast cancer prevention: SERMs come of ageAnthony Howell, D Gareth Evans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2012
Are we ready for online tools in decision making for BRCA1/2 mutation carriers?D Gareth Evans, Anthony Howell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopiesD Gareth Evans, Anthony Howell
Pageof 34